---
schema_version: "1.0.0"
document_id: "78790c232f2905cf717fadcf5fb95806583976756fb09e38db8ee268b223de8b"
company_key: "yc-medcrypt"
company: "MedCrypt"
source_id: "yc-medcrypt-news-import-56918f8bbce9"
canonical_url: "https://www.medcrypt.com/blog/navigating-the-2026-fda-cybersecurity-landscape-lessons-from-the-top-deficiencies"
published_at: "2026-03-04T00:00:00+00:00"
first_seen_at: "2026-07-22T03:50:59.950031+00:00"
fetched_at: "2026-07-28T22:02:33.296770+00:00"
content_hash: "sha256:fcd67049fc6f92a6979f8fca3f196206331c3d4b864e67eb947f8d1e5917255a"
---

# Navigating the 2026 FDA Cybersecurity Landscape: Lessons from the "Top Deficiencies"

## **Navigating the 2026 FDA Cybersecurity Landscape: Lessons from the "Top Deficiencies"**


For medical device manufacturers, 2025 was a watershed year. The FDA’s transition from guidance-driven "recommendations" to **enforceable statutory mandate** under Section 524B of the Food, Drug and Cosmetics (FD&C) Act has fundamentally changed the premarket submission hurdle.


As we move into 2026, the "honeymoon phase" of the FDA cybersecurity guidance is over. Recent data reveals a clear pattern in why submissions are hitting regulatory roadblocks. If you are a Product Security Officer or a Regulatory Affairs Lead, your focus shouldn't just be on *completing* the documentation, but on the **sufficiency** of the evidence.


Reviewing and analyzing actual FDA deficiencies, here the top trends we are seeing, and how to stay ahead of them.


### **1. Penetration Testing: Moving Beyond "Check-the-Box"**


The most significant trend in recent deficiencies is **insufficient penetration testing** . The FDA is no longer satisfied with the mere presence of a report. Instead, we see increasing scrutiny of the findings in a report, including assessing disposition and resolution of findings.


**The Deficiency:** Submissions are being flagged for having "unresolved findings"—even those labeled as "Low" or "Medium" risk—without a documented mitigation, acceptance criteria, or "by-design" justification.


**The Fix:** * **Sufficiency is Key:** Your penetration test must be performed on the final, production-equivalent version of the device. It should cover all system elements, not just the regulated ones.


- **Mitigation:** Every finding in your Pen Test report should be considered as a newly identified risk that should be managed through existing risk assessment processes. If a vulnerability isn't fixed, you must provide an explanation and justification of why the residual risk is acceptable.
- **Retesting:** If you mitigated a High-risk finding, the FDA expects to see evidence of a **retest** to verify the fix worked. (Share your original and re-test reports with FDA to demonstrate this lifecycle coverage.)


### **2. The SBOM Evolution: The "Disclosure Challenge"**


We’ve moved past the "What is an SBOM?" phase into the "Is your SBOM actually useful?" phase.


**The Deficiency:** Incomplete Software Bills of Materials that miss baseline elements like **End of Support (EOS) dates.** More critically, the FDA is now cross-referencing SBOMs against public vulnerability databases (NVD/GitHub Advisories). If a reviewer finds a known CVE (Common Vulnerabilities and Exposures) applicable to a component in your SBOM that you *haven't* disclosed or addressed in your risk assessment, it raises concerns.


**The Fix:**


- **Machine-Readability:** Your SBOM must be in a standard format (like CycloneDX or SPDX).
- SBOM that covers the **required elements** from the CISA Framing Document plus level of support and EOS target dates.
- **Total Transparency:** Do not "filter" your SBOM before submission. If the FDA identifies a vulnerability in your supply chain that you missed, it calls your entire Secure Product Development Framework (SPDF) into question.
- **VEX is Your Friend:** Use a **Vulnerability Exploitability eXchange (VEX)** document to tell the FDA which CVEs in your SBOM *don't* actually impact your device. This prevents reviewers from chasing ghosts and speeds up your approval.


### **3. Premarket Guidance Appendix 1: Your New North Star**


Many manufacturers are still treating **Appendix 1** of the Premarket Guidance as a suggestion. In 2026, the FDA is treating it as a **mandatory checklist** .


**The Deficiency:** Missing one or more core controls—such as Event Detection and Logging, or Cryptographic Implementation—without a robust technical justification.


**The Fix:**


- **Audit Against the 8 Categories:** Ensure your design history file (DHF) explicitly addresses: Authentication, Authorization, Cryptography, Code/Data Integrity, Confidentiality, Event Detection/Logging, Resiliency, and Updatability.
- **Refined Communication:** Use precise language in your submission to explain how these controls are implemented at the architectural level.


### **4. Cybersecurity Labeling (Section VI.A)**


Security is now a core component of the "Instructions for Use" (IFU).


**The Deficiency:** Labeling that fails to provide the end-user (usually a hospital IT admin, clinical engineer, or a clinician) with the information needed to securely configure and operate the device.


**The Fix:**


- **Transparency:** Disclose all connectivity interfaces (Bluetooth, Wi-Fi, etc.), even those disabled by default.
- **Configurability:** If your device is user-configurable, clearly enumerate options and demonstrate consequences for lower security options that can be selected. If not user-configurable, make your user aware of the secure-by-design approach you took to give them confidence in their usage.
- **The "Support Life" Statement:** Clearly state the expected support lifetime for security patches. If a hospital knows you’ll stop patching in five years, they can plan their risk management accordingly.


## **The Bottom Line**


In 2026, the FDA is looking for a **Secure Product Development Framework (SPDF)** that is "built-in," not "bolted-on." They want to see a cohesive story where your Threat Model identifies a risk, your Security Architecture mitigates it, and your Testing proves the mitigation works.


‍
